Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptorum Group Limited stock logo
APM
Aptorum Group
$0.67
-4.6%		$5.04
$0.60
▼
$4.47
$4.24M0.3857,956 shs167,078 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$0.40
-0.3%		$0.40
$0.29
▼
$3.53
$58.36M2.256.05 million shs29,481 shs
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
$0.00
$0.03
▼
$0.38
$21.70MN/A52,703 shs198,200 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptorum Group Limited stock logo
APM
Aptorum Group
0.00%0.00%-90.46%-91.76%-95.09%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
+2.79%+1.02%-3.05%-15.12%-77.68%
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptorum Group Limited stock logo
APM
Aptorum Group
$0.67
-4.6%		$5.04
$0.60
▼
$4.47
$4.24M0.3857,956 shs167,078 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$0.40
-0.3%		$0.40
$0.29
▼
$3.53
$58.36M2.256.05 million shs29,481 shs
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
$0.00
$0.03
▼
$0.38
$21.70MN/A52,703 shs198,200 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptorum Group Limited stock logo
APM
Aptorum Group
0.00%0.00%-90.46%-91.76%-95.09%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
+2.79%+1.02%-3.05%-15.12%-77.68%
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptorum Group Limited stock logo
APM
Aptorum Group
1.00
SellN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.00
Hold$5.501,288.89% Upside
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest IMMP, APM, and PVOTF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2026
Aptorum Group Limited stock logo
APM
Aptorum Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/10/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/29/2026
Aptorum Group Limited stock logo
APM
Aptorum Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/17/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy
6/4/2026
Aptorum Group Limited stock logo
APM
Aptorum Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
5/20/2026
Aptorum Group Limited stock logo
APM
Aptorum Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptorum Group Limited stock logo
APM
Aptorum Group
$430K9.86N/AN/A$2.17 per share0.31
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$6.69M8.72N/AN/A$0.63 per share0.63
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/A$0.01 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptorum Group Limited stock logo
APM
Aptorum Group
-$1.36MN/AN/AN/AN/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$39.78MN/AN/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/A

Latest IMMP, APM, and PVOTF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026H2 2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$0.0258N/AN/AN/A$11.73 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aptorum Group Limited stock logo
APM
Aptorum Group
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptorum Group Limited stock logo
APM
Aptorum Group
N/A
0.78
0.78
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
2.97
N/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A
3.62
3.62

Institutional Ownership

CompanyInstitutional Ownership
Aptorum Group Limited stock logo
APM
Aptorum Group
3.80%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A

Insider Ownership

CompanyInsider Ownership
Aptorum Group Limited stock logo
APM
Aptorum Group
63.99%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
34.77%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptorum Group Limited stock logo
APM
Aptorum Group
306.35 million2.29 millionNot Optionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021147.37 million142.85 millionOptionable
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A171.41 millionN/ANot Optionable

Recent News About These Companies

BetterLife Pharma targets global partners for BETR-001 at JPM Week forums
January 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/betterlife-pharma-targets-global-partners-for-betr-001-at-jpm-week-forums/ar-AA1TGumB
BetterLife Pharma Director and Audit Chair Robert Metcalfe Resigns
December 23, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/betterlife-pharma-director-and-audit-chair-robert-metcalfe-resigns?utm_source=marketbeat.com&utm_medium=referral
BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital
December 11, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/betterlife-pharma-announces-engagement-shanghai-130000188.html
BetterLife Pharma Inc.
May 19, 2025  |  barrons.comhttps://www.barrons.com/market-data/stocks/npau?countrycode=de&iso=xfra
BetterLife appoints Steven Sangha to board of directors
April 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/betterlife-appoints-steven-sangha-to-board-of-directors-1034533552
BetterLife Pharma Achieves Key Cardiac Safety Milestone
November 25, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/betterlife-pharma-achieves-key-cardiac-safety-milestone-1034061813
BetterLife Pharma Inc BETR
November 2, 2024  |  morningstar.comM
Optimistic Buy Rating for BridgeBio Pharma’s BBP-812: Promising Phase 1/2 Results in Canavan Disease Therapy
October 25, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/optimistic-buy-rating-for-bridgebio-pharma-s-bbp-812-promising-phase-1-2-results-in-canavan-disease-therapy-1033895075
BridgeBio Pharma’s BBP-812 Trial Shows Promise for Canavan Disease Amidst Focus on Acoramidis
October 25, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bridgebio-pharma-s-bbp-812-trial-shows-promise-for-canavan-disease-amidst-focus-on-acoramidis-1033894907
BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001
October 23, 2024  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2024/10/23/10093516.htm
With election nearing, BMO analysts don't expect major pharma shake-ups from either candidate
October 14, 2024  |  fiercepharma.comF
Abortion, immigration, drug prices: Where Missouri’s candidates for U.S. Senate stand on the issues
October 13, 2024  |  msn.comhttps://www.msn.com/en-us/news/politics/abortion-immigration-drug-prices-where-missouri-s-candidates-for-u-s-senate-stand-on-the-issues/ar-AA1s5XWD
Democrats snatch a major political football away from Republicans: freedom
August 28, 2024  |  yahoo.comhttps://www.yahoo.com/news/democrats-snatch-major-political-football-125731690.html?soc_src=social-sh&soc_trk=fb&tsrc=fb
RAMM Pharma Corp. (RAMM.CN)
August 22, 2024  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/quote/RAMM.CN/
‘Their skin was peeling off from the chemical burns’: Andhra reactor blast that killed 14 leaves trail of broken homes
August 21, 2024  |  indianexpress.comI
Rewarding careers for animal lovers
August 13, 2024  |  deccanherald.comD
State, city leaders announce deal for quantum technology facility on Chicago’s South Side
July 27, 2024  |  courthousenews.comC
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
April 26, 2024  |  msn.comhttps://www.msn.com/en-us/money/companies/100b-vertex-pharma-working-to-recreate-10b-cystic-fibrosis-success-this-time-focused-on-pain-management-drugs/ar-AA1nJyf5
Jardiance and Ofev propel Boehringer’s human pharma sales
April 17, 2024  |  msn.comhttps://www.msn.com/en-us/money/companies/jardiance-and-ofev-propel-boehringer-s-human-pharma-sales/ar-BB1lKdDd
Vertex Pharma scientist talks about the long road to developing non-addictive painkillers
April 15, 2024  |  abcnews.go.comhttps://abcnews.go.com/Business/wireStory/vertex-pharma-scientist-talks-long-road-developing-addictive-109252088

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aptorum Group stock logo

Aptorum Group NASDAQ:APM

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$0.40 0.00 (-0.33%)
As of 10:33 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

BetterLife Pharma stock logo

BetterLife Pharma OTCMKTS:PVOTF

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas